Eltoprazine also Phase 2B/Phase 3 ready in adult A
Post# of 30066
(Total Views: 431)
Posted On: 03/07/2017 3:42:22 PM
Eltoprazine also Phase 2B/Phase 3 ready in adult ADHD:
Eltoprazine
◾Mechanism: 5-HT1A/1B partial agonist
◾Company: Amarantus Bioscience
◾Status: Phase II clinical trials
Eltoprazine is a drug that was originally developed by Solvay Pharmaceuticals as an antiaggressive agent. It is classified as a phenylpiperazine drug and was intended to be used as a serenic agent, attenuating aggressive behaviors and impulses. Solvay eventually merged with Abbott Pharmaceuticals, who then licensed out Eltoprazine to PsychoGenics, who continued to the game of hot potato, giving licensing rights to Amarantus Bioscience.
The drug functions primarily as a 5-HT1A and 5-HT1B partial agonist, but acts as a 5-HT2C receptor antagonist. It is primarily under investigation for the treatment of levodopa-induced dyskinesia as a result of Parkinson’s disease, but is also in Phase II clinical trials for the treatment of adult ADHD. Thus far, the drug is considered safe, well-tolerated, and has been tested in nearly 700 humans.
Due to its mechanism of action as an antiaggressive agent, it could be suspected that Eltoprazine would be more effective for the treatment of hyperactivity than inattentiveness. However, preliminary evidence suggests that it is significantly effective for the treatment of inattentiveness and hyperactivity when compared to a placebo. This could be another promising non-stimulant intervention for ADHD, though it remains unclear as to how targeting serotonergic receptors improves attentiveness.
◾Source: http://www.amarantus.com/therapeutics-pipelin...ltoprazine
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/1982626
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/2091890
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/21548716
Eltoprazine
◾Mechanism: 5-HT1A/1B partial agonist
◾Company: Amarantus Bioscience
◾Status: Phase II clinical trials
Eltoprazine is a drug that was originally developed by Solvay Pharmaceuticals as an antiaggressive agent. It is classified as a phenylpiperazine drug and was intended to be used as a serenic agent, attenuating aggressive behaviors and impulses. Solvay eventually merged with Abbott Pharmaceuticals, who then licensed out Eltoprazine to PsychoGenics, who continued to the game of hot potato, giving licensing rights to Amarantus Bioscience.
The drug functions primarily as a 5-HT1A and 5-HT1B partial agonist, but acts as a 5-HT2C receptor antagonist. It is primarily under investigation for the treatment of levodopa-induced dyskinesia as a result of Parkinson’s disease, but is also in Phase II clinical trials for the treatment of adult ADHD. Thus far, the drug is considered safe, well-tolerated, and has been tested in nearly 700 humans.
Due to its mechanism of action as an antiaggressive agent, it could be suspected that Eltoprazine would be more effective for the treatment of hyperactivity than inattentiveness. However, preliminary evidence suggests that it is significantly effective for the treatment of inattentiveness and hyperactivity when compared to a placebo. This could be another promising non-stimulant intervention for ADHD, though it remains unclear as to how targeting serotonergic receptors improves attentiveness.
◾Source: http://www.amarantus.com/therapeutics-pipelin...ltoprazine
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/1982626
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/2091890
◾Source: http://www.ncbi.nlm.nih.gov/pubmed/21548716
(2)
(0)